EU: Drug precursors – EU legislation (revised rules)

 

The EU has announced a new legislative initiative to revise its rules on drug precursors.

The proposal seeks to revise the legislation governing the monitoring of trade in drug precursors both within the Union and between the Union and third countries. It addresses a number of shortcomings identified in the recent evaluation of the existing framework, including the need to better regulate so-called designer precursors.

In recent years, drug-related violence and criminal activity have increased across EU Member States, with illicit substances such as cocaine, heroin, opioids and amphetamine-type stimulants posing serious threats to public health and internal security. The drug market has also evolved, with a wider availability of substances that are often more potent or purer and marketed in new forms, developments that are facilitated by the availability of drug precursors. Drug precursors are chemicals required for the illicit manufacture of drugs, although many of these substances also serve important and legitimate industrial purposes.

Recognising the need to prevent the diversion of drug precursors into illicit channels, the United Nations Convention against Illicit Traffic in Narcotic Drugs obliges its Parties to adopt measures to prevent the diversion of substances frequently used in the illicit manufacture of drugs. The Union acceded to the Convention in 1990 and subsequently established a regulatory framework for drug precursors.

At present, the Union implements the Convention through Regulation (EC) No 273/2004 on the monitoring and control of drug precursors within the internal market, and Regulation (EC) No 111/2005 governing trade in such substances between the Union and third countries. These Regulations distinguish between scheduled drug precursors, which are listed and subject to control, and non-scheduled substances, for which no legally binding obligations apply. Scheduled precursors are further categorised according to their role in illicit drug production and the scale of legitimate trade, with corresponding levels of control. In 2013, the powers of competent authorities were clarified to allow national measures to address suspicious transactions involving non-scheduled substances.

Since the adoption of this framework, significant developments have occurred, most notably the rapid emergence of designer precursors—substances with little or no known legitimate use beyond research and innovation. In parallel, the existing obligations applicable to scheduled substances have generated administrative burdens across all categories, while enforcement measures have proven insufficient to ensure consistent application across the Union.

From a security perspective, the proliferation and trafficking of designer precursors pose serious challenges to drug precursor control at the global level. In response, both the United Nations Commission on Narcotic Drugs and the International Narcotics Control Board, in its 2024 report, have recommended extending controls to chemicals closely related to controlled precursors, such as their families or derivatives. This approach has already been adopted by a number of countries, including the United States, Canada, Argentina, Mexico and, more recently, China, and is increasingly being pursued at multilateral level through the Commission on Narcotic Drugs.

Drug precursor control is a core element of drug supply-reduction policy under the EU Drugs Strategy 2021–2025, with the accompanying EU Drugs Action Plan emphasising the need to address the risks posed by designer precursors. The 2023 EU Roadmap to fight drug trafficking and organised crime further underlines the importance of developing innovative and more agile regulatory approaches to respond to new methods of illicit drug production. In addition, the European Internal Security Strategy (ProtectEU) announced the development of a new EU Drugs Strategy and Action Plan to disrupt trafficking routes and criminal business models, while the Commission’s 2025 Work Programme announced the preparation of new rules on drug precursors.

At the same time, drug precursors play an essential role in numerous legitimate industries, including pharmaceuticals, flavourings and fragrances, batteries, cosmetics, textiles, oil refining, water treatment, food additives, explosives, rubber production, fertilisers, plastics and dyes. In 2023, approximately 4 000 licences or registrations to trade in drug precursors were active in the Union, with small and medium-sized enterprises accounting for around 92 % of operators. The supply chains for these chemicals involve a wide range of actors, from large-scale manufacturers to specialised producers, distributors and logistics providers. Given that the chemical industry is a strategic sector in the Union, supplying over half of its output to other industries, it is essential to ensure that legitimate operators can fully benefit from the Single Market.

Against this background, the proposal aims to strengthen the prevention of the diversion of drug precursors for illicit drug manufacture, while simplifying rules and procedures for legitimate trade. In particular, the introduction of specific provisions on designer precursors and innovative mechanisms for their inclusion in the regulatory framework will enable faster and more effective action to prevent diversion. In addition, increased digitalisation of regulatory processes will allow certain obligations to be automated, significantly reducing administrative burdens and compliance costs for economic operators and national authorities alike.